Don't miss

Replay


LATEST SHOWS

ENCORE!

Music show: hot hits for the summer season

Read more

FOCUS

Canada: Religious sponsorship of refugees creates controversy

Read more

BUSINESS DAILY

Verizon set to buy Yahoo's internet business

Read more

IN THE PAPERS

As Democrats gather, Russian subplot sparks intrigue

Read more

IN THE PAPERS

Bernard Cazeneuve, the political punching bag

Read more

THE INTERVIEW

Erdogan to rid Turkish institutions of ‘separatist cancer’ after coup attempt

Read more

ENCORE!

The best of summer music festivals in France

Read more

FRANCE IN FOCUS

Going for gold: French athletes train for Rio Olympics

Read more

#TECH 24

Digital beauty

Read more

Health

Doctors start first human trial of stem cells

Text by News Wires

Latest update : 2010-10-11

US doctors have begun testing human stem cells on a patient for the first time after securing a license to use the controversial cells to treat people with spinal injuries.

AFP - US doctors have begun treating the first patient with embryonic stem cells as part of the first human study of the controversial treatment authorized by the government, the Geron Corporation said Monday.
  
The patient was enrolled at the Shepherd Center spinal cord and brain injury rehabilitation hospital in Atlanta, Georgia, where Geron began clinical trials of their GRNOPC1 human embryonic stem cells in treating patients with devastating spinal cord injuries.
  
The trial comes just 11 years after Geron began working with human embryonic stem cells in 1999, when "many predicted that it would be a number of decades before a cell therapy would be approved for human clinical trials," said Thomas Okarma, Geron's president and CEO.
  
"Initiating the GRNOPC1 clinical trial is a milestone for the field of human embryonic stem cell-based therapies," Okarma said.
  
Geron got clearance in January last year to conduct human trials of GRNOPC1 embryonic stem cells, which are highly versatile, primitive cells capable of developing into any tissue.
  
Preclinical studies have shown that GRNOPC1 significantly improved locomotor activity of animals with spinal cord injuries when injected seven days after the injury.
  
Participants in the study must be newly injured and receive GRNOPC1 between seven and 14 days of sustaining their injury.
  
David Apple, Shepherd Center's medical director, said the clinical trial was a key step forward in attempts to find a cure for paralysis in people with spinal cord injury.
  
The ultimate goal is to inject GRNOPC1 cells into the spines of paralyzed human volunteers in the hope that this will prompt damaged nerve cells to regrow, enabling the patients to eventually recover feeling and movement.

Date created : 2010-10-11

  • USA

    Court lifts ban on funding for embryonic stem cell research

    Read more

  • BIOETHICS

    South Korean stem cell scientist convicted for faked research

    Read more

COMMENT(S)